|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||1.83|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2024 - 01 Mar 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby’s predicted
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.